The latest financial statement is for the quarter ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | -18,899 | -19,417 | -15,095 |
| Depreciation and amortization | 54 | 53 | 40 |
| Stock-based compensation | 1,096 | 1,096 | 916 |
| Amortization of operating lease right-of-use asset | 135 | 132 | 129 |
| Non-cash interest expense | -1 | -1 | 3 |
| Accretion on marketable securities | -142 | -145 | -125 |
| Prepaid expenses and other current assets | -284 | -1,777 | 1,942 |
| Other assets | 9 | 0 | 37 |
| Operating lease liability | -159 | -216 | -86 |
| Deferred revenue, net of deferred contract acquisition costs | -284 | -239 | -225 |
| Accounts payable and accrued expenses | 294 | 3,201 | -2,424 |
| Net cash used in operating activities | -17,631 | -13,759 | -18,846 |
| Purchases of laboratory and other equipment | 26 | 60 | 65 |
| Sales and maturities of marketable securities | 6,000 | 2,000 | 8,000 |
| Purchases of marketable securities | 5,870 | 2,034 | 8,723 |
| Net cash used in investing activities | 104 | -94 | -788 |
| Net proceeds from sale of common stock under open market sale agreement, net of offering costs | 2,313 | 27,928 | 397 |
| Net proceeds from sale of common stock under 2019 employee stock purchase plan | 70 | 0 | 161 |
| Issuance of note payable for insurance policy | 0 | 0 | 1,020 |
| Net proceeds from option exercises | 7 | - | - |
| Repayment of notes payable | 278 | 274 | 90 |
| Net cash provided by financing activities | 2,112 | 27,654 | 1,488 |
| Net change in cash and cash equivalents | -15,415 | 13,801 | -18,146 |
| Cash and cash equivalents at beginning of period | 62,786 | 67,131 | - |
| Cash and cash equivalents at end of period | 47,371 | 62,786 | - |
Vistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc. (VTGN)